Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 9.37% | Reduce −9.8% | 401,505 | $98.80 | $40M | −43,500 | −$2M |
| STXS - Stereotaxis | 6.59% | Hold | 13,680,554 | $2.04 | $28M | — | — |
| RVMD - Revolution Medicines | 5.55% | Add +1.2% | 517,994 | $45.35 | $23M | +6,100 | +$4M |
| CYTK - Cytokinetics | 4.97% | Hold | 398,100 | $52.80 | $21M | — | — |
| Merus | 4.87% | Add +0.8% | 412,573 | $49.96 | $21M | +3,128 | −$4M |
| ATRC - Atricure | 4.25% | Add +0.4% | 641,673 | $28.04 | $18M | +2,500 | +$3M |
| IDYA - Ideaya Biosciences | 3.53% | Add +11.7% | 471,410 | $31.68 | $15M | +49,197 | +$110K |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.53% | Hold | 102,500 | $145.60 | $15M | — | — |
| ASND - Ascendis Pharma A/S | 3.16% | Add +10.6% | 89,572 | $149.31 | $13M | +8,600 | +$2M |
| AXGN - Axogen | 3.10% | Hold | 935,894 | $14.02 | $13M | — | — |
| Blueprint Medicines | 2.66% | Add +16.2% | 121,763 | $92.50 | $11M | +17,000 | −$28K |
| XENE - Xenon Pharmaceuticals | 2.55% | Hold | 273,739 | $39.37 | $11M | — | — |
| DAWNGBX — | 2.47% | Add +12.6% | 750,363 | $13.93 | $10M | +83,900 | +$1M |
| SNDX - Syndax Pharmaceuticals | 2.40% | Reduce −19.8% | 526,702 | $19.25 | $10M | −130,372 | −$3M |
| BHVN - Biohaven | 2.21% | Reduce −14.4% | 187,130 | $49.97 | $9M | −31,600 | +$2M |
| TNDM - Tandem Diabetes Care | 2.05% | Hold | 204,208 | $42.41 | $9M | — | — |
| Kalvista Pharmaceuticals | 1.98% | Reduce −10.3% | 723,678 | $11.58 | $8M | −83,295 | −$1M |
| NBIX - Neurocrine Biosciences | 1.89% | Reduce −2.8% | 69,615 | $115.22 | $8M | −2,000 | −$2M |
| KURA - Kura Oncology | 1.89% | Reduce −3.6% | 408,368 | $19.54 | $8M | −15,132 | −$740K |
| VKTX - Viking Therapeutics | 1.88% | Reduce −33.6% | 125,616 | $63.31 | $8M | −63,501 | −$2M |
| EWTX - Edgewise Therapeutics | 1.44% | Reduce −21.5% | 227,906 | $26.69 | $6M | −62,291 | +$856K |
| URGN - Urogen Pharma | 1.38% | Reduce −2.2% | 458,915 | $12.70 | $6M | −10,085 | −$2M |
| BCRX - Biocryst Pharmaceuticals | 1.20% | Reduce −5.3% | 667,000 | $7.60 | $5M | −37,500 | +$715K |
| DXCM - Dexcom | 1.04% | Hold | 65,552 | $67.04 | $4M | — | — |
| Keros Therapeutics | 1.01% | Add +8.9% | 73,754 | $58.07 | $4M | +6,000 | +$1M |
| ALEC - Alector | 1.00% | Hold | 912,928 | $4.66 | $4M | — | — |
| RCUS - Arcus Biosciences | 0.93% | Add +1.4% | 256,717 | $15.29 | $4M | +3,500 | +$69K |
| LKFT - Galapagos | 0.89% | Hold | 130,175 | $28.79 | $4M | — | — |
| PODD - Insulet | 0.87% | Hold | 15,900 | $232.75 | $4M | — | — |
| ALKS - Alkermes | 0.80% | Hold | 120,700 | $27.99 | $3M | — | — |
| LRMR - Larimar Therapeutics | 0.76% | Reduce −22.8% | 494,274 | $6.55 | $3M | −145,700 | −$1M |
| CATX - Perspective Therapeutics | 0.73% | Reduce −0.6% | 230,322 | $13.35 | $3M | −1,312 | +$765K |
| 2seventy Bio | 0.70% | Reduce −40.0% | 630,029 | $4.72 | $3M | −420,680 | −$1M |
| Acelyrin | 0.70% | Reduce −13.1% | 602,894 | $4.93 | $3M | −90,715 | −$87K |
| ALLO - Allogene Therapeutics | 0.69% | Add +73.5% | 1,050,118 | $2.80 | $3M | +445,018 | +$2M |
| AQST - Aquestive Therapeutics | 0.69% | Add +11.2% | 589,561 | $4.98 | $3M | +59,561 | +$2M |
| IPSC - Century Therapeutics | 0.69% | Hold | 1,704,232 | $1.71 | $3M | — | — |
| CATBUSD - Astria Therapeutics | 0.66% | Reduce −7.3% | 254,165 | $11.01 | $3M | −20,000 | +$303K |
| BCYC - Bicycle Therapeutics | 0.65% | Hold | 122,200 | $22.63 | $3M | — | — |
| STOK - Stoke Therapeutics | 0.60% | Hold | 207,427 | $12.29 | $3M | — | — |
| BWAY - Brainsway | 0.55% | Reduce −15.6% | 251,346 | $9.24 | $2M | −46,309 | +$516K |
| LXEO - Lexeo Therapeutics | 0.54% | New | 250,583 | $9.04 | $2M | +250,583 | +$2M |
| ARAY - Accuray | 0.52% | Hold | 1,222,358 | $1.80 | $2M | — | — |
| SPRY - Ars Pharmaceuticals | 0.51% | Reduce −38.0% | 148,294 | $14.50 | $2M | −90,900 | +$115K |
| INGN - Inogen | 0.48% | Hold | 208,790 | $9.70 | $2M | — | — |
| CNTA - Centessa Pharmaceuticals | 0.45% | Reduce −2.1% | 120,351 | $15.99 | $2M | −2,531 | +$815K |
| MLYS - Mineralys Therapeutics | 0.42% | Add +23.1% | 146,500 | $12.11 | $2M | +27,500 | +$382K |
| AUTL - Autolus Therapeutics | 0.42% | Add +40.4% | 486,667 | $3.63 | $2M | +140,000 | +$560K |
| Immatics | 0.39% | Hold | 145,000 | $11.41 | $2M | — | — |
| Iteos Therapeutics | 0.39% | Add +11.9% | 161,584 | $10.21 | $2M | +17,224 | −$493K |
| PRQR - Proqr Therapeutics | 0.39% | Hold | 905,582 | $1.82 | $2M | — | — |
| CMPS - Compass Pathways | 0.36% | Hold | 243,210 | $6.30 | $2M | — | — |
| GPCR - Structure Therapeutics | 0.35% | Add +580.0% | 34,000 | $43.89 | $1M | +29,000 | +$1M |
| IMVT - Immunovant | 0.35% | Add +8.5% | 51,996 | $28.51 | $1M | +4,080 | +$217K |
| Regulus Therapeutics | 0.33% | Hold | 895,200 | $1.57 | $1M | — | — |
| Gossamer Bio | 0.33% | Add +0.7% | 1,419,262 | $0.9864 | $1M | +10,000 | +$130K |
| Holding | 0.29% | Hold | 1,350,708 | $0.9053 | $1M | — | — |
| Mediwound | 0.28% | Reduce −48.2% | 64,479 | $18.06 | $1M | −60,000 | −$767K |
| Sutro Biopharma | 0.27% | Hold | 329,579 | $3.46 | $1M | — | — |
| Polypid | 0.25% | Add +66.9% | 308,497 | $3.44 | $1M | +123,651 | +$266K |
| Nyxoah S A | 0.24% | Hold | 108,108 | $9.55 | $1M | — | — |
| BNTX - Biontech Se | 0.24% | New | 8,500 | $118.77 | $1M | +8,500 | +$1M |
| Adicet Bio | 0.20% | Hold | 600,000 | $1.44 | $864K | — | — |
| Compugen | 0.19% | Reduce −3.2% | 447,202 | $1.81 | $809K | −15,000 | +$33K |
| ACRV - Acrivon Therapeutics | 0.19% | Reduce −7.4% | 112,414 | $7.00 | $787K | −8,937 | +$83K |
| Sage Therapeutics | 0.18% | Reduce −6.9% | 108,200 | $7.22 | $781K | −8,000 | −$481K |
| GRAL - Grail | 0.16% | New | 48,800 | $13.76 | $671K | +48,800 | +$671K |
| ADCT - Adc Therapeutics SA | 0.15% | Hold | 204,081 | $3.15 | $643K | — | — |
| BDTX — | 0.13% | New | 125,000 | $4.35 | $544K | +125,000 | +$544K |
| Tourmaline Bio | 0.12% | Reduce −74.8% | 19,110 | $25.71 | $491K | −56,872 | −$486K |
| Biomx | 0.10% | New | 401,136 | $1.02 | $409K | +401,136 | +$409K |
| Masimo | 0.09% | Hold | 3,000 | $133.33 | $400K | — | — |
| VSTM - Verastem | 0.09% | New | 127,700 | $2.99 | $382K | +127,700 | +$382K |
| APRE - Aprea Therapeutics | 0.09% | Hold | 137,174 | $2.75 | $377K | — | — |
| FHTX - Foghorn Therapeutics | 0.08% | Reduce −10.0% | 37,664 | $9.31 | $351K | −4,186 | +$110K |
| NGNE - Neurogene | 0.08% | Reduce −29.3% | 7,775 | $41.96 | $326K | −3,225 | −$74K |
| Adaptimmune Therapeutics | 0.08% | Hold | 341,064 | $0.9504 | $324K | — | — |
| ANRO - Alto Neuroscience | 0.07% | Reduce −77.7% | 26,786 | $11.44 | $306K | −93,214 | −$976K |
| Neuronetics | 0.06% | Hold | 313,717 | $0.7598 | $238K | — | — |
| CMPX - Compass Therapeutics | 0.05% | Hold | 116,882 | $1.84 | $215K | — | — |
| Nevro | 0.05% | Add +35.7% | 38,000 | $5.59 | $212K | +10,000 | −$23K |
| Spero Therapeutics | 0.04% | Hold | 125,000 | $1.34 | $168K | — | — |
| Karyopharm Therapeutics | 0.04% | Hold | 192,678 | $0.8300 | $160K | — | — |
Showing top 50 of 83 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Morphic | 1.89% | Exit | 0 | $34.07 | $8M | −231,748 | −$8M |
| PRCT - Procept Biorobotics | 0.20% | Exit | 0 | $61.10 | $855K | −13,994 | −$855K |
| Syros Pharmaceuticals | 0.17% | Exit | 0 | $5.16 | $701K | −135,850 | −$701K |
| TERN - Terns Pharmaceuticals | 0.14% | Exit | 0 | $6.81 | $586K | −86,000 | −$586K |
| ORIC - Oric Pharmaceuticals | 0.06% | Exit | 0 | $7.08 | $255K | −36,000 | −$255K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2